US Oncologist Survey: Optimizing Treatment for Metastatic Breast Cancer


#30865

59pages

Assessment Group

$ 8900

In Stock

 

Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer. 

 

Primary research on the oncology prescribing data that you are missing, directly from high-prescribing US oncologists regarding metastatice breast cancer: what they prescribe, when, and why. Case highlights include:

 

  • Triple negative metastatic breast cancer
  • Triple positive metastatic breast cancer
  • ER/PR positive HER2neu negative metastatic breast cancer
  • Metastatic breast cancer with multiple comorbidities

 

This report allows you to:

 

  • Understand what occurs in the oncologist’s office with actual patients
  • Access the most up-to-date prescribing trends
  • Gain actionable data for developing & improving market strategies
  • Pinpoint needs of your target audience
  • Design messages to advance brand performance
  • Focus resources to maximize the effectiveness of your budget
  • Understand where your competitor’s product fits

Table of Contents

 

Executive Summary

 

Chapter 1: Introduction

Table 1. Treatment Options in Metastatic Breast Cancer

 

Chapter 2: Respondent Demographics

Table 2. Eligibility Criteria for Survey Participation

Figure 2.1 Gender of Survey Respondents

Figure 2.2 Years since Medical School Graduation

Figure 2.3 Practice Settings

Figure 2.4 Practices in NCI Cancer Centers

Figure 2.5 Geographic Settings

Figure 2.6 Survey Respondents by State’s Breast Cancer Mortality

Figure 2.7 Number of Physicians in Practice Groups

Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen

 

Chapter 3: Treatment of a Patient with Triple Negative Metastatic Breast Cancer

Choice of chemotherapy regimen, triple negative metastatic breast cancer

Figure 3.1

Single chemotherapy choices, triple negative metastatic breast cancer

Figure 3.2

Combination chemotherapy choices, triple negative metastatic breast cancer

Figure 3.3

Factors influencing treatment of triple negative metastatic breast cancer

Figure 3.4

Confidence managing patient with triple negative metastatic breast cancer

Figure 3.5

Other agents appropriate to include in treatment of triple negative metastatic breast cancer

Figure 3.6

Treatment of progressive triple negative metastatic breast cancer

Figure 3.7

Single chemotherapy agent, progressive triple negative metastatic breast cancer

Figure 3.8

Combination chemotherapy, progressive triple negative metastatic breast cancer

Figure 3. 9

Barriers to optimal treatment of progressive triple negative metastatic breast cancer

Figure 3.10

Changing therapy to manage neuropathy

Figure 3.11

Recommended treatment of progressive triple negative metastatic breast cancer with BRCA-1 mutation

Figure 3.12

Single agent chemotherapy, progressive triple negative metastatic breast cancer with BRCA-1 mutation

Figure 3.13

Combination chemotherapy, progressive triple negative metastatic breast cancer with BRCA-1 mutation

Figure 3.14

 

Chapter 4: Treatment of Patient with Triple Positive Metastatic Breast Cancer

Next step for patient with triple positive metastatic breast cancer

Figure 4. 1

Treatment of progressive disease, triple positive metastatic breast cancer

Figure 4.2

Single chemotherapy choices for progressive triple positive metastatic breast cancer

Figure 4.3

Combination chemotherapy, progressive triple positive metastatic breast cancer

Figure 4.4

Factors influencing treatment of progressive triple positive metastatic breast cancer

Figure 4.5

Treatment regimen for continued progression of triple positive metastatic breast cancer

Figure 4.6

Decisions regarding the use of lapatinib in progressive triple positive metastatic breast cancer

Figure 4.7

Management of progressive disease, triple positive metastatic breast cancer

Figure 4.8

 

Chapter 5: Patient with ER/PR Positive HER2Neu Negative Metastatic Breast Cancer

Confidence managing patient with ER/PR positive HER2/neu negative metastatic breast cancer

Figure 5.1

Other than analgesics, treatment of patient’s hip pain with ER/PR positive HER2/neu negative metastatic breast cancer

Figure 5.2

Treatment with ER/PR positive HER2/neu negative metastatic breast cancer

Figure 5.3

Factors influencing treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer

Figure 5.4

Next systemic treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer

Figure 5.5

 

Chapter 6: Patient with Metastatic Breast Cancer with Multiple Comorbidities

Confidence managing patient with metastatic breast cancer with multiple comorbidities

Figure 6.1

Barriers to managing patient, metastatic breast cancer with multiple comorbidities

Figure 6.2

Treatment in addition to the aromatase inhibitor for patient’s metastatic breast cancer with multiple comorbidities

Figure 6.3

Next treatment regimen for progressive metastatic breast cancer with multiple comorbidities

Figure 6.4

Factors influencing treatment for progressive metastatic breast cancer with multiple comorbidities

Figure 6.5

 

Chapter 7: Summary

Appendix A: Survey Instrument

NA

NA